Research findings from Merck & Company, Inc. update understanding of life sciences

Research findings, 'A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies,' are discussed in a new report. "In an effort to develop agents to test the NMDA hypofunction hypothesis of schizophrenia, benchmark compounds from a program to discover potent, selective, competitive glycine transporter 1 (GlyT1) inhibitors were radiolabeled in order to further study the detailed pharmacology of these inhibitors and the distribution of GlyT1 in brain. We here report the in vitro characterization of [35S](S)-2-amino-4-chloro-N-(1-(4-phenyl-1-(propylsulfonyl)piperidin-4-yl)ethyl)benzamide ([35S]ACPPB), a radiotracer developed...

Want to see the full article?

• Purchase this article for only $3.00